Janssen has kicked off a Phase II/III programme assessing Tremfya in Crohn’s Disease.
News
Gov’t launches £10 antimicrobial research competition
The government has launched a £10 million research competition to encourage the development of novel approaches to combating antimicrobial resistance and improving infection prevention and control.
Takeda gets US nod for Shire buy
Takeda says it has received unconditional clearance from the US Federal Trade Commission for the proposed acquisition of Shire.
NICE advises restricted use of antibiotics for COPD
The National Institute for Health and Care Excellence is advising healthcare professionals to restrict use of antibiotics for chronic obstructive pulmonary disease (COPD).
CTI, Servier’s Pixuvri fails in post-marketing trial
A late-stage trial of Servier and CTI BioPharma’s Pixuvri in combination with Roche’s MabThera has failed to hit targets in B-cell non-Hodgkin lymphoma, putting its conditional approval in Europe in jeopardy.
Three cancer treatments approved for use on NHS Scotland
Three treatments have been approved for NHS funding in Scotland, bringing new options for gastroenteropancreatic tumours, lung and kidney cancers, but patients with multiple sclerosis will be unable to access Roche’s Ocrevus following a rejection by the SMC.
May names Hancock as new health and social care secretary
Prime Minister Theresa May has named West Suffolk MP Matt Hancock as the new secretary of state for health and social care.
NHS England clears specialised treatments for NHS use
NHS England has approved routine funding for a stream of new specialised treatments, including stroke-reducing heart implants and a life changing surgical procedure for children with cerebral palsy.
Vertex, NHS England no closer to Orkambi settlement
Vertex and NHS England remain locked in a battle over the provision of cystic fibrosis drug Orkambi, seemingly no closer to a settlement that would allow patients access to the drug on the NHS.
PAH patients in England denied access to Actelion’s Uptravi on NHS
Actelion’s Uptravi will not be funded on the NHS for patients with Pulmonary Arterial Hypertension (PAH), after the drug failed to make it into NHS England’s latest round of specialised commissioning approvals.
Clovis’ PARP inhibitor Rubraca under EU review in maintenance setting
European regulators have agreed to review Clovis’ application to expand the use of its PARP inhibitor Rubraca in the region.
If you love a challenge, ENTER NOW
The PharmaTimes Marketer of the Year competition is celebrating it’s 25th anniversary and with a number companies including Sanofi, PharmaLex, Thornton & Ross, Roche, Bayer, Consilient Health, Cycle Pharmaceuticals and others already entered, it could just be the most exciting one to date.
Europe recalling some valsartan meds on safety fears
The European Medicines Agency is reviewing medicines containing valsartan supplied by a facility in China after a potentially cancer-causing impurity was detected.
Chinese firms eyeing up Sinclair Pharma
Shares in UK group Sinclair Pharma shot up nearly 40 percent after it confirmed interest from Chinese firms with regard to a possible take-over.
Eisai, Biogen’s Alzheimer’s candidate shows promise in PhII trial
At last some good news for Alzheimer’s research, as Eisai and Biogen’s experimental anti beta-amyloid therapy BAN2401 hit targets in a Phase II trial in patients with the disease.
